Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. We report updated results from RESONATE in these tradi...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770586/
https://www.ncbi.nlm.nih.gov/pubmed/28592889
http://dx.doi.org/10.1038/leu.2017.175

Ejemplares similares

Ejemplares similares